IHAM

Integral Health Asset Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 40.53%
This Quarter Est. Return
1 Year Est. Return
+40.53%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.07B
AUM Growth
+$168M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
98
New
Increased
Reduced
Closed

Top Buys

1
+$26.9M
2
+$26.3M
3
+$23.5M
4
LLY icon
Eli Lilly
LLY
+$19.5M
5
CRL icon
Charles River Laboratories
CRL
+$17.4M

Top Sells

1
+$19.6M
2
+$15.6M
3
+$12.8M
4
KRYS icon
Krystal Biotech
KRYS
+$10.8M
5
BSX icon
Boston Scientific
BSX
+$10.7M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
76
Cigna
CI
$80.6B
– –
-10,000
CRNX icon
77
Crinetics Pharmaceuticals
CRNX
$3.86B
– –
-125,000
DYN icon
78
Dyne Therapeutics
DYN
$2.44B
– –
-450,000
FATE icon
79
Fate Therapeutics
FATE
$190M
– –
-700,000
GILD icon
80
Gilead Sciences
GILD
$150B
– –
-175,000
GMED icon
81
Globus Medical
GMED
$8.41B
– –
-50,000
IQV icon
82
IQVIA
IQV
$37.5B
– –
-30,000
KRYS icon
83
Krystal Biotech
KRYS
$5.39B
– –
-60,000
LH icon
84
Labcorp
LH
$23.2B
– –
-20,000
MASI icon
85
Masimo
MASI
$8.03B
– –
-45,000
MREO
86
Mereo BioPharma
MREO
$318M
– –
-800,000
PTCT icon
87
PTC Therapeutics
PTCT
$5.27B
– –
-100,000
PTN
88
DELISTED
Palatin Technologies
PTN
– –
-1,000,000
RGEN icon
89
Repligen
RGEN
$9.36B
– –
-20,000
RNA icon
90
Avidity Biosciences
RNA
$7.17B
– –
0
TEVA icon
91
Teva Pharmaceuticals
TEVA
$21.7B
– –
-500,000
VKTX icon
92
Viking Therapeutics
VKTX
$3.89B
– –
0
VSTM icon
93
Verastem
VSTM
$489M
– –
-500,000
XENE icon
94
Xenon Pharmaceuticals
XENE
$3.14B
– –
0
ACLX icon
95
Arcellx
ACLX
$4.7B
– –
0
ARWR icon
96
Arrowhead Research
ARWR
$5.25B
– –
-175,000
ASND icon
97
Ascendis Pharma
ASND
$12.2B
– –
-100,000
BBIO icon
98
BridgeBio Pharma
BBIO
$10.4B
– –
-100,000
1 2 3
4